On today's episode of the Zacks Friday Finish Line, Associate Stock Strategist Ryan McQueeney and Editor Maddy Johnson discuss this week's political drama and highlight JPMorgan's new competitor to free trading app Robinhood. Later, the hosts recap earnings results from Urban Outfitters, Target, and Alibaba.
Make sure to subscribe and leave the show a rating on Apple Podcasts !
It was an interesting week in Washington D.C. as the White House scrambled to respond to escalating legal situations involving Trump associates Paul Manafort and Michael Cohen, but investors shrugged those stories aside.
One of the week's top market headlines was the news that JPMorgan JPM is launching a new mobile trading application, You Invest, which will feature free and discounted stock and ETF trades. The app is a likely a response to popular free trading platform Robinhood, and it sent a clear message to digital brokerages like TD AmeritradeAMTD and E-Trade ETFC .
Urban Outfitters managed to surpass earnings estimates on the back of impressive comps growth, with the specialty retailer tallying robust performance across all its brands-but especially Free People.
Meanwhile, Target saw better-than-expected earnings results, impressive revenue, and same-store sales growth of 6.5% as recent store rejuvenation plan and supply chain adjustments started to pay off for the big-box retailer.
Chinese tech behemoth Alibaba BABA also joined the fun this week, notching revenue growth which exceeded 60%. The e-commerce company is now a formidable cloud computing company, and its "new retail" plan keeps progressing.
Maddy and Ryan discuss all of these stories, filling investors in on the key facts they need to know and providing their own perspectives on the headlines.
Is Alibaba really the Amazon of China? What makes Urban Outfitters unique? How much fun is it to shop at a Target these days?
Hear the Finish Line team's answers to each of these questions, and more, only on today's show!
As a reminder, if you feel that we missed something, or if you want us to cover a different story, shoot us an email at email@example.com. Make sure to check out all of our other audio content at zacks.com/podcasts , and remember to subscribe and leave us a rating on Apple Podcasts.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.